Tag Archives | Alzheimer Disease

2018 J.P.Morgan Healthcare Conference #5: Companies to Watch

J.Morgan Healthcare Conference: Companies to Watch We are still reviewing 2018 J.P.Morgan Healthcare presentations for inclusion in our portfolio but here are two longer term opportunities to track for milestones and growth: Accelerate Diagnostics and Denali Therapeutics. Accelerate Diagnostics (AXDX). Accelerate is an emerging in vitro diagnostic company providing solutions for serious infections . The […]

Continue Reading 0

2018 J.P.Morgan Healthcare Conference #3: ABBV and BMY…Update

http://idsn.com/wp-json/oembed/1.0/embed?url=http://idsn.com/products-and-accessories/ Sluggish Early Trading in Biotech Tracks NASDAQ Down 0.14%% Promising Year for M&A and Tax Cuts Improving Bottom Line There is a little follow-on to Tuesday’s rally bringing prices for major ETFs above where they were last week. The biotech screen reverted to flat/green where it was on Monday.There were a few big winners that […]

Continue Reading 0

Alert: Alzheimer’s Drug Fails in Clinical Trial-Stocks Sink: ACIU,BIIB,LLY…Update-1

http://defineddesignsblog.com/2014/11/gift-guide-hostess.html Another clinical trial failure for an Alzheimer’s Disease in a late stage trial triggered a pre-market sell-off.  Both Biogen (BIIB) -aducanumab- and Lilly (LLY)- solanezumab -drugs in development are engineered antibodies that attack beta amyloid targets in the brain. At the close 11/23: ACIU $11.53 down 15.84% BIIB $305.93 down 3.83% LLY $68 down 10.51% […]

Continue Reading 0

Life Science News Update:$700M in Fed Research Center at NIH; AD Diagnosis

Will the GOP cut the NIH budget? Turf battles at the Institutes to follow. Who knew there were only two breakthroughs in mental health drugs: Thorazine and Lithium? Federal Research Center Will Help Develop Medicines – NYTimes.com Most experts believe the PET Imaging procedure can be helpful. Alzheimer’s Scan Might Help Spot Disease Alzheimer’s Association […]

Continue Reading 0

Medivation hangover -stock stable

Despite a bunch of way-too-late analyst downgrades (JPMorgan, Roth, Hapoalim) MDVN stock is up 1%+ at $13.25 on volume of 8.8M shares. But there are two interesting articles coming out of the Medivation drama: Robert Langreth writing in Forbes offers the potential of better results on two upcoming trials and comments from Lon Schneider, an […]

Continue Reading 0

Medivation Chills Biotech Sector

Medivation (MDVN) released disappointing Phase III results for its Alzheimer drug, known as dimebon, saying that the drug was ineffective in treating cognitive decline or behavioral disorders. The stock plunged 67% to 13 as of midday trading on Wednesday. In a joint release Medivation and its partner Pfizer (PFE) said its two Phase III trials […]

Continue Reading 0